减肥药企业Kailera纳斯达克上市：市值31亿美元恒瑞医药成大赢家

雷递网04-19

雷递网雷建平 4月19日减肥药企业Kailera Therapeutics(股票代码：“KLRA”）日前在美国纳斯达克上市，发行价为16美元，发行3906万股，募资总额为6.24亿美元。Kailera已收到某些现有股东（包括与贝恩资本私募股权公司、贝恩资本生命科学公司和卡塔尔投资局有关联的实体）的非约束性意向书，表示有兴趣以每股首次公开发行价格购买本次发行中总计约2.25亿美元的普通股，条款与...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2628766952?lang=zh_CN&edition=full","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260419/6391221034231146037652788.jpeg","is_english":false,"pubTime":"2026-04-19 15:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2628766952","market":"sh","top_or_hot":-1,"title":"减肥药企业Kailera纳斯达克上市：市值31亿美元 恒瑞医药成大赢家","media":"雷递网","content":"<div>\n<p>雷递网 雷建平 4月19日减肥药企业Kailera Therapeutics(股票代码：“KLRA”）日前在美国纳斯达克上市，发行价为16美元，发行3906万股，募资总额为6.24亿美元。Kailera已收到某些现有股东（包括与贝恩资本私募股权公司、贝恩资本生命科学公司和卡塔尔投资局有关联的实体）的非约束性意向书，表示有兴趣以每股首次公开发行价格购买本次发行中总计约2.25亿美元的普通股，条款与...</p>\n\n<a href=\"https://www.leinews.com/n33340/detail.html\">网页链接</a>\n\n</div>\n","source":"leinews_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>减肥药企业Kailera纳斯达克上市：市值31亿美元 恒瑞医药成大赢家</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n减肥药企业Kailera纳斯达克上市：市值31亿美元 恒瑞医药成大赢家\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-19 15:45 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.leinews.com/n33340/detail.html><strong>雷递网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>雷递网 雷建平 4月19日减肥药企业Kailera Therapeutics(股票代码：“KLRA”）日前在美国纳斯达克上市，发行价为16美元，发行3906万股，募资总额为6.24亿美元。Kailera已收到某些现有股东（包括与贝恩资本私募股权公司、贝恩资本生命科学公司和卡塔尔投资局有关联的实体）的非约束性意向书，表示有兴趣以每股首次公开发行价格购买本次发行中总计约2.25亿美元的普通股，条款与...</p>\n\n<a href=\"https://www.leinews.com/n33340/detail.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.leinews.com/n33340/detail.html","article_id":"2628766952","we_media_id":null,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260419/6391221034231146037652788.jpeg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2628766952","pubTimestamp":1776584754,"columns":[],"sourceInfo":{"source_id":"leinews_highlight","name":"雷帝触网"},"weMediaInfo":null,"summary":"减肥药企业Kailera Therapeutics(股票代码：“KLRA”）日前在美国纳斯达克上市，发行价为16美元，发行3906万股，募资总额为6.24亿美元。","collect":0,"end_time":0,"defaultTopTitle":"leinews.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600276":"恒瑞医药","BK4007":"制药","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","QQQE":"Direxion NASDAQ-100 Equal Weighted Index Shares","BK1191":"制药","ONEQ":"Fidelity NASDAQ Composite Index ETF","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","PSQ":"做空纳斯达克100指数ETF-ProShares","BK0060":"抗癌","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","QYLG":"Nasdaq 100 Covered Call & Growth ETF","QQQA":"ProShares Nasdaq-100 Dorsey Wright Momentum ETF","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","QDTE":"Roundhill N-100 0DTE Covered Call Strategy ETF","IYW":"美国科技ETF-iShares","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU0359201612.USD":"贝莱德中国基金A2","BK1147":"投资银行业与经纪业","QQQ":"纳指100ETF","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","01276":"恒瑞医药","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","FTEC":"Fidelity MSCI Information Techno","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","SQQQ":"纳指三倍做空ETF","BK0196":"行业龙头","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU1997245177.USD":"安联神洲A股基金","BK0028":"国家队","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","NVIW.SI":"NVDA 3xLongSG261006","BK0239":"医药制造","KLRA":"Kailera Therapeutics, Inc.","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","QQQY":"Defiance Nasdaq 100 Enhanced Options & 0DTE Income ETF","QQQM":"NASDAQ100指数ETF-Invesco","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","GPIQ":"GOLDMAN SACHS NASDAQ 100 CORE PREMIUM INCOME ETF","QLD":"2倍做多纳斯达克100指数ETF-ProShares","LU1146622755.USD":"安本中国A股股票基金A Acc","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","JEPQ":"JPMorgan Nasdaq Equity Premium Income ETF","TQQQ":"纳指三倍做多ETF","QQQJ":"Invesco NASDAQ Next Gen 100 ETF","TQQY":"GraniteShares YieldBOOST QQQ ETF","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","BK0183":"MSCI概念","BK0188":"融资融券","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","QID":"两倍做空纳斯达克指数ETF-ProShares","BK0012":"证金概念","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A"},"translate_title":"Weight loss drug company Kailera listed on Nasdaq: market value of US$3.1 billion Hengrui Medicine became a big winner","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/54b81b5fecb18ada7833512e7a3c47fc","symbols_score_info":{"600276":1.87,"GPIQ":0.6,"QDTE":0.6,"NVIW.SI":0.6,"IYW":0.6,"TQQY":0.6,"QLD":0.6,"QQQJ":0.6,"QID":0.6,"QQQE":0.6,"ONEQ":0.6,"SQQQ":0.6,"QQQA":0.6,"QQQ":0.6,"NQmain":0.6,"MNQmain":0.6,"01276":1.87,"JEPQ":0.6,"PSQ":0.6,"QYLG":0.6,"QQQY":0.6,"QQQM":0.6,"TQQQ":0.6,"KLRA":1.97,"FTEC":0.6},"content_text":"雷递网 雷建平 4月19日减肥药企业Kailera Therapeutics(股票代码：“KLRA”）日前在美国纳斯达克上市，发行价为16美元，发行3906万股，募资总额为6.24亿美元。Kailera已收到某些现有股东（包括与贝恩资本私募股权公司、贝恩资本生命科学公司和卡塔尔投资局有关联的实体）的非约束性意向书，表示有兴趣以每股首次公开发行价格购买本次发行中总计约2.25亿美元的普通股，条款与本次发行的其他购买者相同。Kailera开盘价和收盘价均为26美元，较发行价上涨62.5%；以收盘价计算，公司市值为30.67亿美元。2025年10月，Kailera才宣布完成6亿美元融资，由新投资者贝恩资本私募股权公司牵头，新投资者和现有投资者参与融资，以支持肥胖治疗后期差异化组合的持续发展。B轮的其他新投资者包括领先的共同基金和投资者，包括Adage Capital Management LP、加拿大养老金计划投资委员会（CPP Investments）、Invus、Janus Henderson investors、Perseverance Capital、卡塔尔投资局（QIA）、Royalty Pharma、Surveyor Capital（Citadel公司）、T.Rowe Price Associates。Kailera现有投资者Atlas Venture、Bain Capital Life Sciences、RTW Investments和Sirona Capital也参与了本轮融资。年亏损1.49亿美元Kailera是一家临床阶段生物技术公司，专注于通过推进多元化的管道来提升下一个肥胖护理时代，为肥胖患者提供选择。肥胖是一种慢性、进行性和衰弱性疾病，影响全球10亿多人，需要长期综合治疗。由于肥胖是200多种合并症的驱动因素，也是发病率和死亡率增加的重要因素。Kailera的愿景是提供类别领先的肥胖管理药物，使人们有能力恢复健康并改变生活。以肥胖为首要关注点，Kailera建立一个多元化候选产品线，专门用于满足当前治疗领域的关键需求，Kailera认为该候选产品具有最大的减肥潜力。Kailera的旗舰产品是代号为KAI-9531（即恒瑞的瑞普泊肽/HRS9531）的GLP-1/GIP双受体激动剂，正在进行全球III期临床试验，被视为诺和诺德Wegovy与礼来Zepbound的潜在有力竞争者。Kailera无收入，2024年净亏损为2.2亿美元，2025年净亏1.49亿美元。恒瑞医药是股东2026年1月5日，Kailera才任命Doug Pagán为其首席财务官。IPO前，BCLS Fund IV Investments持股为24.8%，BCPE Perseus Investor持股为21.1%，Jiangsu Hengrui Pharmaceuticals持股为13.6%，RTW Investments持股为12.1%，CPP Investment Board Private Holdings持股为5.9%，Atlas Venture Fund持股为5.5%。Ronald C. Renaud, Jr.持股为1.9%，Michael Gladstone持股为5.5%。IPO后，BCLS Fund IV Investments持股为17.8%，BCPE Perseus Investor持股为15.1%，Jiangsu Hengrui Pharmaceuticals持股为9.8%，RTW Investments持股为8.7%，CPP Investment Board Private Holdings持股为4.2%，Atlas Venture Fund持股为4%。Ronald C. Renaud, Jr.持股为1.3%，Michael Gladstone持股为4%。———————————————雷递由媒体人雷建平创办，若转载请写明来源。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2628766952","isCrawlerRequest":true}

减肥药企业Kailera纳斯达克上市：市值31亿美元 恒瑞医药成大赢家

精彩评论

减肥药企业Kailera纳斯达克上市：市值31亿美元恒瑞医药成大赢家